Note: This grant page has been archived and is very likely out of date.

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Suggest an update

Deadline: The deadline for this grant has passed

Grant amount: Up to US $1,710,531

Fields of work: Infectious & Parasitic Diseases Respiratory Diseases & Systems

Applicant type: For-Profit Business

Funding uses: Non-clinical Behavioral

Location of project: Anywhere in the world

Location of residency: United States

Overview:

NOTE: Applications are due by 5 p.m. submitter's local time. 

The goal of this RFA is to solicit direct to Phase II SBIR proposals for development of novel, non-traditional, approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. This FOA is seeking applications for innovative portable devices able to produce reliable associations between biomarkers emanating from skin and the oral cavity to patients with symptomatic and asymptomatic COVID-19. Specifically, biosensing devices are expected to target skin or the oral cavity as sampling sites. Skin biosensing must detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in passive and noninvasive manner for use at the point of care. In addition to VOCs, oral biosensing technologies may target a wealth of biological, chemical and physical biosignatures representative of COVID-19 that can be sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity. Leveraging the accessibility of human skin and the oral cavity, this FOA seeks

  1. To advance novel biosensing technologies that are innovative, safe, and effective, and
  2. To implement such technologies into devices with integrated artificial intelligent (AI) systems for the detection, diagnosis, prediction, prognosis and monitoring of COVID-19 in clinical, community and everyday settings.

For skin monitoring, the device can include Electronic-nose (E-nose) technology or Gas Chromatography (GC). Thus, we are calling this program, the SCENT (Screening for COVID-19 by E-Nose Technology). Biosensing devices for the oral cavity can be technologies that have been thoroughly characterized as safe and effective in preclinical studies. Non-invasive, real-time, continuous or periodic measurements of VOCs and other biomarkers in breath, and emanating from oral tissues as signatures of onset, progression, and resolution of COVID-19 are desirable.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

This page was last reviewed August 24, 2020 and last updated August 24, 2020